//Nityr

Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in the Kingdom of Saudi Arabia

By | May 13th, 2020|News, Nityr|

Cycle Pharmaceuticals and Medherant Partner to Develop Medicines using the TEPI Patch® Technology

By | May 5th, 2020|News, Nityr|

Cycle Pharmaceuticals is pleased to announce that it has signed an agreement with Baylor Genetics

By | December 18th, 2019|News, Nityr|

Health Canada has approved an updated version of the NITISINONE TABLETS’ Product Monograph

By | November 18th, 2019|News, Nityr|

Cycle Pharmaceuticals and Catalent Partner to Develop Treatments for Rare Diseases using Zydis ODT Technology

By | October 31st, 2019|News, Nityr|

NITYR (nitisinone) Tablets for tyrosinaemia type 1 will be available with fully subsidised access on the Life Saving Drugs Program across Australia

By | April 28th, 2019|News, Nityr|

Cycle Pharmaceuticals’ NITYR (nitisinone) tablets receives marketing authorization in Chile

By | November 22nd, 2018|News, Nityr|

Longer shelf life for NITYR (nitisinone) tablets for HT-1 in the U.S. granted by the FDA

By | November 19th, 2018|News, Nityr|

Cycle Pharmaceuticals Receives Approval for Updated Infant Administration for NITYR (nitisinone) Tablets for HT-1 in U.S.

By | November 12th, 2018|News, Nityr|

Aprecia Pharmaceuticals and Cycle Pharmaceuticals Partner to Develop 3D-Printed Orphan Drugs

By | December 12th, 2017|News, Nityr|